厄贝沙坦片联合硝苯地平控释片对慢性肾衰竭伴高血压患者治疗的临床研究

Clinical study of irbesartan tablets combined with nifedipine controlled release tablets in treatment of chronic renal failure patients with hypertension

目的探讨厄贝沙坦片(安博维)在慢性肾衰竭伴高血压患者治疗过程中的治疗效果。方法选取2013年9月～2017年9月在我院进行诊治的84例慢性肾衰竭伴高血压患者为研究对象,采用抽签法将所有研究对象随机分为对照组与观察组各42例,对照组患者给予厄贝沙坦片(安博维)治疗,观察组在对照组的用药基础上加用硝苯地平控释片(拜新同),比较两组研究对象治疗前后的血压变化情况、肾功能及生活质量。结果观察组治疗后的收缩压和舒张压分别为(121.0±17.8)mm Hg和(76.8±10.1)mm Hg,对照组为(124.6±19.8)mmHg和(78.4±9.7)mmHg,观察组血压变化略优于对照组,差异无统计学意义(P> 0.05);观察组治疗后的血清尿素氮(BUN)和血清肌酐(SCr)分别为(16.2±5.1)mmol/L和(212±58.3)μmol/L,对照组为(18.5±5.2)mmol/L和(253.6±60.2)μmol/L,观察组治疗后的肾功能指标显著优于对照组,差异具有统计学意义(P <0.05)。治疗后,两组生活质量评分均有所提高,观察组高于对照组,差异具有统计学意义(P <0.05)。结论利用厄贝沙坦片(安博维)联合硝苯地平控释片(拜新同)对慢性肾衰伴高血压患者进行治疗,能够同时达到降低血压和保护肾功能的效果,其临床应用价值较高。

Objective To investigate the effect of irbesartan tablets （Aprovel） in the treatment of chronic renal failure with hypertension. Methods From September 2013 to September 2017, 84 patients with chronic renal failure and hypertension were selected as subjects. All the subjects were randomly divided into control group and observation group with 42 cases in each group. The patients in control group were treated with irbesartan tablets （Aprovel）. The patients in observation group were treated with nifedipine controlled-release tablets （Adalat） on the basis of the drugs in control group. The changes of blood pressure, renal function and quality of life were compared between the two groups before and after treatment. Results The systolic and diastolic blood pressures in the observation group were （121.0 ± 17.8） mm Hg and （76.8 ± 10.1） mm Hg respeetively after treatment, while those in the eontrol group were （124.6 ± 19.8） mm Hg and （78.4 ± 9.7） mm Hg. The changes of blood pressure in the observation group were slightly better than those in the eontrol group （P 〉 0.05）. The serum BUN and SCr in the observation group were （16.2 ± 5.1） mmol/L and （212 ± 58.3） μmol/L respeetively after treatment, while those in the eontrol group were （18.5± 5.2） mmol/L and （253.6 ± 60.2） μmol/L. The renal function indexes in the observation group were significantly better than those in the control group （P〈 0.05）. After treatment, the quality of life scores of the two groups were improved, the observation group was higher than the control group, the difference was statistically significant （P 〈 0.05）. Conclusion Irbesartan tablets （Aprovel） combined with nifedipine controlled-release tablets （Adalat） can reduce blood pressure and protect renal function in patients with chronic renal failure and hypertension, and its clinical value is high.